Orphazyme A/S ORPH:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EST
12.22quote price arrow down-0.19 (-1.53%)
Volume
7,039
52 week range
8.89 - 13.98

...

Loading . . .

KEY STATS

  • Open11.86
  • Day High12.24
  • Day Low11.37
  • Prev Close12.41
  • 52 Week High13.98
  • 52 Week High Date01/20/21
  • 52 Week Low8.89
  • 52 Week Low Date11/02/20
  • Market Cap350.13M
  • Shares Out27.04M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Orphazyme A/S News

There is no recent news for this security.

Latest ORPH News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The...
Georges Gemayel Ph.D.
Chairman
Bo Hansen M.D. Ph.D.
Vice Chairman
Anders Fink Vadsholt
Chief Financial Officer
Address
Ole Maaloees Vej 3, Copenhagen N
Koebenhavn
2200
Denmark